Holen Sie sich die Stockscreener-App
20.87
14.92%
2.71
Handel nachbörslich:
20.87
Sionna Therapeutics Inc Aktie (SION) Neueste Nachrichten
Sling Therapeutics, Inc. Appoints Ken Lock as Chief Commercial Officer - MarketScreener
Sionna Therapeutics reports annual meeting results By Investing.com - Investing.com South Africa
Sionna Therapeutics Holds Annual Stockholders Meeting - TipRanks
Sionna Therapeutics reports annual meeting results - Investing.com
Sionna's experimental CFTR modulators show promise in preclinical tests - Cystic Fibrosis News Today
Odyssey Therapeutics pulls plug on IPO plans - The Business Journals
Odyssey Ends Quest for Nasdaq, Pulls IPO Application After Nearly 5 Months - BioSpace
Odyssey pulls back from IPO plans as public markets remain frozen - Endpoints News
Sionna Therapeutics advances CF treatment with new data By Investing.com - Investing.com South Africa
Sionna Therapeutics advances CF treatment with new data - Investing.com India
Sionna Therapeutics Announces Presentation of Preclinical Data that Demonstrate Proprietary Dual Combination Therapies Enable Full CFTR Correction in CFHBE Model - GlobeNewswire
Breakthrough Clinical Data: New Dual Therapy Achieves Complete CFTR Correction in Cystic Fibrosis Model - Stock Titan
NBD1 stabilizers safe in healthy volunteers, Sionna says - Cystic Fibrosis News Today
Petri Dish: PepGen halts work on Duchenne drug; Needham biotech announces layoffs - The Business Journals
2 Soaring Stocks Wth More Upside Potential - AOL.com
Transcript : Sionna Therapeutics, Inc.Special Call - marketscreener.com
Sionna advances cystic fibrosis treatments to new trials By Investing.com - Investing.com South Africa
Newly-Listed Sionna Therapeutics Touts Positive Data From Lung Disease Candidate In Healthy Volunteer Trial - Benzinga
Stifel analysts reiterate buy rating on Sionna Therapeutics stock By Investing.com - Investing.com Canada
Sionna Therapeutics Announces Positive Phase 1 Results For SION-719, SION-451 In Cystic Fibrosis - Nasdaq
Sionna advances cystic fibrosis treatments to new trials - Investing.com Australia
Sionna Therapeutics Reports Positive Phase 1 Trial Results - TipRanks
Sionna Therapeutics Announces Positive Phase 1 Data for NBD1 Stabilizers SION-719 and SION-451 and Advances Both Programs in Clinical Development for Cystic Fibrosis - The Manila Times
Sionna Therapeutics Announces Positive Phase 1 Data For Nbd1 Stabilizers Sion-719 And Sion-451 And Advances Both Programs In Clinical Development For Cystic Fibrosis - marketscreener.com
Sionna Therapeutics Announces Positive Phase 1 Data for - GlobeNewswire
Sionna selects which cystic fibrosis drug it will study in a mid-stage test - Endpoints News
Sionna Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference - GlobeNewswire
3 No-Brainer Healthcare Stocks to Buy in June - AOL.com
Sionna Therapeutics (NASDAQ:SION) Stock Price Down 6% – Here’s What Happened - Defense World
Why Summit Therapeutics Plunged Today - AOL.com
3 High-Flying Stocks That Could Soar Even More - AOL.com
Sionna Therapeutics to Present Preclinical Data on CFTR Modulators at European Cystic Fibrosis Conference - Nasdaq
Sionna Therapeutics to Present Preclinical Data During Oral Session at the 48th European Cystic Fibrosis Conference - GlobeNewswire
Sionna Therapeutics (NASDAQ:SION) Shares Gap Down Following Weak Earnings - Defense World
Sionna Therapeutics Phase 1 Topline Data For Nbd1 Stabilizers Sion-719 & Sion-451 Expected This Quarter - marketscreener.com
Sionna Therapeutics Reports First Quarter 2025 Financial Results - GlobeNewswire
Private equity firms invested in Sionna Therapeutics, Inc. (NASDAQ:SION) copped the brunt of last week's US$56m market cap decline - simplywall.st
While individual investors own 26% of Sionna Therapeutics, Inc. (NASDAQ:SION), private equity firms are its largest shareholders with 56% ownership - Yahoo Finance
Why Vertex Pharmaceuticals Stock Is a Screaming Buy on the Dip - AOL.com
Sionna Therapeutics to Present at The Citizens Life Sciences Conference 2025 - The Manila Times
Revolutionary Cystic Fibrosis Treatment Developer Sionna Takes Stage at Major Healthcare Conference - Stock Titan
2 Beaten-Down Stocks With Incredible Upside Potential - AOL.com
OrbiMed-backed biotech looks to challenge Vertex in cystic fibrosis by 'drugging the undruggable' - Endpoints News
Alcoa Posts Weak Revenue, Joins QXO And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
Q1 IPOs Rise From Q4, But Unstable Markets Could Slow New Offerings - insights.citeline.com
In 2025, biotech IPOs were supposed to bounce back. It hasn't happened yet. - The Business Journals
Sionna Therapeutics (NASDAQ:SION) Trading Down 4.2%What's Next? - MarketBeat
Sionna Therapeutics (NASDAQ:SION) Reaches New 1-Year Low on Disappointing Earnings - Defense World
Stifel maintains Buy rating on Sionna Therapeutics stock at $32 target - Investing.com Australia
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):